Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Chicago, IL
NPI: 1306028451Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Satyajit's Phone NumberMobile
Get Satyajit's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 37 | 255 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 32 | 131 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 16 | 58 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 16 | 16 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 13 | 15 |
Authors: Richard Larson, Emily Curran, Lucy Godley, Olatoyosi Odenike, Kristen Pettit, Andrew Artz, Margaret Green, Amy Wang, Michael Thirman
Publication Date: 2018-01-05
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.
Authors: Boglarka Gyurkocza, Doris Ponce, Ying Taur, Anthony Sung, Eric Pamer, Sergio Giralt, Juliet Barker
Publication Date: 2017-03-16
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011
Lead Sponsor: Miltenyi Biotec B.V. & Co. KG
Collaborators: University of Chicago, Ohio State University, Masonic Cancer Center, University of Minnesota
Intervention / Treatment: DEVICE: Interventions
Lead Sponsor: AltruBio Inc.
Intervention / Treatment: BIOLOGICAL: Neihulizumab (ALTB-168)
